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Skin and soft tissue infections
Wound healing
A B S T R A C T
Skin and soft tissue infections (SSTIs) have high rates of morbidity and mortality associated. Despite the suc-
cessful treatment of some SSTIs, those affecting the subcutaneous tissue, fascia, or muscle delay the healing
process and can lead to life-threatening conditions. Therefore, more effective treatments are required to deal
with such pathological situations. Recently, wound dressings loaded with antimicrobial agents emerged as viable
options to reduce wound bacterial colonization and infection, in order to improve the healing process. In this
review, an overview of the most prominent antibacterial agents incorporated in wound dressings along with
their mode of action is provided. Furthermore, the recent advances in the therapeutic approaches used in the
clinic and some future perspectives regarding antibacterial wound dressings are also discussed.
1. Introduction
Skin is the largest and outermost organ that covers the entire body.
Therefore, above all, skińs primary function is to protect underlying
muscles, bones, ligaments and internal organs from external biological,
chemical, mechanical and physical agents [1,2]. Furthermore, skin is
also involved in sensation, temperature regulation, immunological
surveillance, prevention of water loss (dehydration) and synthesis of
vitamin D3 [3]. However, the structure and functions performed by this
organ can be affected by cuts, burns, surgical incisions or illnesses, such
as diabetes [4]. After skin structure be compromised, its structure and
functions must be re-established, as soon as possible to ensure the body
homeostasis. To accomplish that, the wound healing process begins
almost immediately after a skin injury occurs, in order to avoid the risk
of bacterial contamination [5]. Non-healing wounds usually appear
after this type of contamination occur [4].
Skin and soft tissue infections (SSTIs) are the most common types of
infections and they affect approximately 14 million people every year
in the United States [6,7]. Depending on the etiology and severity of the
microbial invasion, SSTIs can range from minor superficial to life-
threatening infections [8]. In the initial stage of the infectious process,
gram-positive organisms such as Staphylococcus aureus (S. aureus) and
Streptococcus pyogenes (S. pyogenes) are the dominant organisms in-
volved, while gram-negative organisms like Escherichia coli (E. coli) and
Pseudomonas aeruginosa (P. aeruginosa) are only found in later stages of
the process, i.e. when a chronic wound is developed [7].
In a healthy human being, infection is avoided, by activating the
immune system for abolishing the invading pathogens. In this process,
macrophages initiate the migration to the wound site and subsequently
perform phagocytosis of the pathogens (which are destroyed in a pha-
golysosome or by nitric oxide production). In a later stage of infection,
the immune response is performed by the activation of lymphocytes T
helper which secrete interferon-γ and CD40 ligand to coordinate the
immune adaptive and humoral response to kill and remove the invading
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bacteria [9]. However, if the immune system is not able to remove the
pathogen, infection occurs and causes the deterioration of granulation
tissue, growth factors and extracellular matrix components (collagen,
elastin and fibrin), thus compromising the normal wound healing pro-
cess [10,11]. Therefore, it is fundamental to develop wound dressings
that are capable of preventing bacteria penetration into the wound or
avoid microorganisms’ growth. To accomplish that, different ap-
proaches involving materials with intrinsic bactericidal activity, mod-
ified surface or incorporating antimicrobial agents, are being used to
produce wound dressings displaying bactericidal activity [12].
Herein, an overview of the most prominent antibacterial agents
incorporated in wound dressings along with their mode of action is
provided. Furthermore, the recent advances in the therapeutic ap-
proaches used in the clinic and some future perspectives regarding
antibacterial wound dressings are also discussed. Due to the higher
prevalence of bacterial infections, this review does not provide any data
concerning SSTIs caused by viral, fungal or parasites (protozoa, hel-
minths, and ectoparasites).
2. Wound pathophysiology and the wound healing process
Wounds occur when a tissue is disrupted or the cellular integrity is
compromised due to mechanical, physical or metabolism-related issues
[13]. According to the duration and nature of the healing process, skin
wounds can be classified as acute or chronic. An acute wound occurs
suddenly, as a consequence of abrasions, avulsions, burns, incisions,
lacerations and punctures, and have associated an healing time that is
dependent on the size and number of layers of skin that have been af-
fected [12,14]. Under normal physiological conditions, the restoration
of the epidermal structure is highly efficient, however when a chronic
wound occur, it is characterized by displaying a defective healing
process, that do not allow skin to be repaired in an orderly and timely
manner [15]. Based on etiology, the Wound Healing Society classifies
chronic wounds into four categories: pressure, diabetic, venous and
arterial insufficiency ulcers [16]. Bacterial colonization usually occurs
in chronic wounds and it is considered as a primary cause of chronic
inflammation [17].
The healing process comprises a cascade of precisely synchronized
events in which are involved both resident and migratory cell popula-
tions, extracellular matrix components and soluble mediators [18]. This
process includes five distinct phases: hemostasis, inflammation, mi-
gration, proliferation and remodeling [19]. In the first phase, hemos-
tasis, a fibrin clot is formed to prevent blood loss through vasocon-
striction as well as to avoid microbial contamination [20]. The
inflammatory phase begins almost simultaneously with hemostasis and
it involves the recruitment of neutrophils (that engulf bacteria and
decontaminate the wound through proteases and antimicrobial pep-
tides secretion and by producing reactive oxygen intermediates),
monocytes/macrophages (monocytes differentiate into macrophages to
remove apoptotic neutrophils and other cells and secrete cytokines and
multiple growth factors), and lymphocytes that exert a specific response
against microbes (B–lymphocytes produce antibodies, while T–lym-
phocytes secrete cytokines involved in cytolytic activity) [20–22]. The
migration and proliferative phases begin with fibroblast migration to
the wound site and differentiation into myofibroblasts to produce ex-
tracellular matrix components like fibronectin, hyaluronic acid, col-
lagen and proteoglycan, that are involved in the production of extra-
cellular matrix (ECM), new blood vessels and re-epithelization [20].
Maturation, or remodeling, is the last stage of the wound healing pro-
cess and in this phase all processes that were activated after injury are
ceased [19].
In order to ensure an effective wound healing process, it is funda-
mental to maintain a controlled set conditions at the wound site (i.e.
oxygenation, temperature and high availability of vitamins, minerals,
and trace elements) that sustain the complex cellular activity during
this process [23]. However, chronic wounds, burns, diabetic ulcers and
post-surgical wounds have extended healing times and, in some cases,
even fail. For example, burn wounds usually display high levels of
exudate, which provides a moist and nutrient-rich environment that
promotes bacterial growth, namely Pseudomonas species [24]. These
bacteria produce virulence factors that mediate a number of processes
like adhesion, nutrient acquisition, leucocyte killing and bloodstream
invasion. Furthermore, these microorganisms are also able to produce
endotoxins that promote pro-inflammatory cytokines expression, such
as interleukin-1 and tumor necrosis factor-α, that ultimately lead to
wound inflammation [25–27]. Wounds exhibiting an extended in-
flammation, show a high content of metalloproteinases (MMPs) that are
involved in the degradation of ECM components, thus avoiding the
formation of the granulation tissue and consequently delaying the
healing [11,28].
On the other hand, patients suffering from Diabetes mellitus (DM)
have an impaired protective sensation and altered pain response, which
makes them vulnerable to trauma and extrinsic forces. Diabetic wounds
are characterized by their dry and keratinized aspect, that usually crack
or suffer fissures more easily, leading to an extended healing time [29].
Therefore, patients with DM are predisposed to cutaneous infections
occur, namely those caused by S. pyogenes and S. aureus [30].
3. Wound dressings displaying antimicrobial activity
In 1987, Gristina came up with the expression “race for the surface”
to describe the competition that occurs between cells and bacteria for
colonize a surface. Bacteria are inherently favored in this event, due to
is natural ability to colonize both biological and non-biological surfaces
[31]. An open wound is a favorable niche for microbial colonization
[32]. Generally, the majority of infected wounds present polymicrobial
and are usually contaminated by pathogens found in the surrounding
environment, i.e. endogenous microbes living in the mucous mem-
branes, and by the microflora available on the adjacent skin [33]. In the
initial stages of chronic wound formation, gram-positive organisms,
specifically S. aureus, are predominant. In the later stages, gram-nega-
tive E. coli and Pseudomonas species are observed and tend to invade
deeper layers of skin causing significant tissue damage. Furthermore,
Staphylococci and Streptococci species are also found in 50% of chronic
wounds [7].
Nowadays, bacterial contamination of skin wounds are responsible
for the high rates of morbidity and mortality [34]. To address this
health issue, different labs around the world started to develop anti-
microbial wound dressings to prevent wound contamination [35]. The
wound dressings develop up to now have been produced with different
materials (synthetic or natural) and with various physical forms
(sponges, hydrogels, hydrocolloids, films, membranes). These different
formulations have distinct properties that make them suitable for the
treatment of a particular type of wound. For example, sponges exhibit a
huge porosity, provide thermal insulation and sustain a moist en-
vironment at the wound site. Nonetheless, the sponges are mechanically
weak, may provoke skin maceration and are unsuitable for the treat-
ment of third-degree burns or wounds with dry eschar [36,37]. On the
other hand, hydrogels are characterized by their capacity to store high
amounts of water within their 3D polymeric network, which allow them
to provide a moist environment to the wound. However, hydrogels
display weak mechanical properties, thus demanding a secondary
dressing [38,39]. Furthermore, hydrocolloids are easily removed by
saline or sterilized water, non-adherent, present high density and are
painless dressings. Nevertheless, hydrocolloids display some dis-
advantages that may limit their use, i.e. they may be cytotoxic, display
an unpleasant odor, present a low mechanically stability and maintain
an acid pH at the wound site [40,41]. Films used as wound dressings are
impermeable to bacteria, allow healing monitorization and are painless.
However, this type of dressing are hard to handle, adhere to the wound
bed and cause exudate accumulation [14,40]. In turn, membranes
(specially electrospun membranes) are known to act as physical barriers
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as well as to reproduce the 3D architecture of native ECM. Moreover,
their high surface-to-volume ratio and interconnected pores are crucial
to assure cell proliferation, gas exchange, nutrient supply, and to con-
trol fluid loss. The main drawbacks associated with membrane use are
originated by the materials and solvents used in their production
[42,43].
So far, to improve dressing antimicrobial properties different agents
have been incorporated within their structure. Those antimicrobial
agents comprise essentially antibiotics (e.g. tetracycline, ciprofloxacin,
gentamicin and sulfadiazine), nanoparticles (e.g. silver nanoparticles)
and natural products (e.g. honey, essential oils and chitosan) [33]. A
schematic representation of a polymeric antimicrobial dressing, de-
signed to act as a physical barrier that protects the wound from mi-
crobial invasion and supports fibroblasts migration and differentiation,
is presented in Fig. 1.
4. Antibacterial agents used to functionalize wound dressings
4.1. Antibiotics
The discovery of natural compounds that exhibit antimicrobial ac-
tivity was a major breakthrough in the treatment of infectious diseases,
like SSTIs [44]. Although thousands of antibiotics are known, less than
1% is currently in use in the clinic, due to toxicity related issues or lack
of uptake by the host cells [45]. Up to now, only aminoglycosides [46],
beta-lactams [47], glycopeptides [48–50], quinolones [51], sulphona-
mides [52,53] and tetracyclines [54,55] have been used to produce
wound dressings displaying antimicrobial activity. The incorporated
antibiotics can interfere with a function/feature of the bacteria struc-
ture or on their metabolic pathways through one of the following four
mechanisms (as represented in Fig. 2):
1. Inhibition of bacterial cell wall synthesis: β-lactams and gly-
copeptides are among the classes of antibiotics that interfere specifi-
cally with the cell wall biosynthesis [56]. For example, β-lactams (in-
cluding penicillins, carbapenems and cephalosporins) block the
crosslinking of peptidoglycan units, by inhibiting the peptide bond
formation reaction catalysed by Penicillin Binding Proteins (PBPs).
Contrariwise, glycopeptides antibiotics (i.e. vancomycin) inhibit pep-
tidoglycan synthesis, by binding peptidoglycan units and by blocking
transglycosylase and PBPs activity [57]. Such events will impact on the
shape of the bacteria and eventually lead to their lysis due to the high
internal osmotic pressure [58].
2. Blockage of key metabolic pathways: The presence of folate
pathway in many pathogenic microorganisms and its absence in
mammals, has made this pathway an attractive target for antimicrobial
drugs [59]. Some antibiotics mimic the folic acid structure (e.g. sul-
phonamides) and allow their competitive binding to bacterial enzymes.
Such interferes with the production of DNA, RNA and proteins, leading
to the disruption of bacteria proliferation [60].
3. Interference on protein synthesis: Antibiotics that interfere
with protein synthesis can be divided into two subclasses: the 50S and
the 30S inhibitors. According to the data available in literature, only the
30S inhibitors have been used to treat skin infections. Aminoglycosides
(i.e. streptomycin) and tetracyclines are antibiotics that act as 30S ri-
bosome-inhibitors, by obstructing the access of aminoacyl-tRNAs to the
ribosome [60,61].
4. Inhibition of nucleic acids synthesis: Some antibiotics have the
capacity to interfere with nucleic acid synthesis, by inhibiting the re-
plication or transcription processes. Antibiotics that inhibit nucleic acid
synthesis usually target topoisomerase II and topoisomerase IV of bac-
teria and RNA polymerase activity, thereby preventing the production
of mRNA [56,60]. The quinolone group of synthetic antimicrobial drugs
acts by converting their targets (DNA gyrase and topoisomerase IV),
into enzymes that fragment the bacterial chromosome [62].
Among the different antibiotics incorporated so far in wound dres-
sings, tetracycline [63], ciprofloxacin (CIP) [64,65], gentamicin [66]
and sulfadiazine [52,67] have been the most used. García et al. devel-
oped films based on chitosan (CS), at concentration of 1% (w/v), and
modified-hybrids CS-weisocyanate as functional carriers of CIP. The
obtained results revealed that these films loaded with antibiotic were
able to inhibit S.aureus and P. aeruginosa growth, and the films’ in-
hibitory activity was proportional to the antibiotic content loaded
Fig. 1. Representation of the healing process in an open (a) and antimicrobial wound dressing covered (b) wound: The open wound is vulnerable to bacterial contamination, leading to an
extended inflammatory phase and an increased expression of metalloproteinases that are involved in the degradation of ECM components and also inhibit the formation of new
granulation tissue. When the antimicrobial dressing was used to cover the wound bed, it acts as a physical barrier to prevent pathogens entrance into the wound or to kill the invading
microorganisms. In addition, the antimicrobial dressing supports the healing process by stimulating the immune system and fibroblast/keratinocyte migration.
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within their structure [68]. Moreover, Heyu Li and co-workers pro-
duced electrospun fibers with thermoresponsive polymers, (poly(N-
isopropylacrylamide) (PNIPAAm) and poly (l-lactic acid-co-ɛ-capro-
lactone) (PLCL)) at different ratios with a total concentration of
polymer of 10% (w/v) and loaded them with CIP to confer antibacterial
activity to the fibers. Their results showed CIP-loaded fibers displayed
similar inhibitory growth effect against E. coli and S. aureus [69].
On the other hand, Wei Shao and colleagues developed a tetra-
cycline hydrochloride-loaded bacterial cellulose (BC) composite mem-
brane. The antibacterial activity of the produced composite was in-
vestigated by both disc diffusion method and plate count method
against E. coli, S. aureus and Bacillus subtilis (B. subtilis) [55]. The
composite membrane presented a higher inhibitory effect against E. coli
(45.7 mm) than for S. aureus (38.5mm) and B. subtilis (34mm). Re-
garding the plate counting method, the wound dressing reduce E. coli
growth by 99.98%, while for S. aureus and B. subtilis the membrane was
able to completely inhibit their growth [55]. Furthermore, Chen et al.
fabricated an alginate-CS hydrogel dressing loaded with gelatin mi-
crospheres containing tetracycline hydrochloride to be used as a skin
substitute. The bactericidal activity assays showed that the composite
gel dressing was able to inhibit E. coli and S. aureus growth [63]. Re-
cently, a semisynthetic derivative of tetracycline (glycylcyclines) was
approved for the treatment of SSTIs. Tigecycline was the first member
of this new class of antibiotics and presents a similar mechanism of
action to that exhibited by tetracycline (30S ribosome-inhibitors),
however it was designed to avoid the bacteria efflux-mediated re-
sistance mechanisms [70,71]. Dhanalakshmi and colleagues en-
capsulated tigecycline within chitosan nanoparticles (CNPs), and used
them for treating infected chronic wounds [72]. Subsequently, Nimal
et al. incorporated tigecycline loaded chitosan nanoparticles into a
chitosan-platelet-rich plasma (PRP) hydrogel. The produced system
showed an improved antibacterial activity against S. aureus [73].
Monteiro et al. produced a gentamicin-loaded liposome im-
mobilized at the surface of CS nanofibers mesh (NFM), to confer this
electrospun membrane antibacterial activity. The obtained results
showed that the produced mesh was able to inhibit E. coli, P. aeruginosa
and S. aureus growth [66]. Fajardo et al. incorporated silver sulfadia-
zine (AgSD) into CS/chondroitin sulfate (CHI) film to improve their
applicability as a wound dressing. The antibacterial activity of the CHI/
CS/AgSD was evaluated through the determination of their capacity to
inhibit P. aeruginosa and S. aureus growth. The produced film presented
an inhibitory growth effect against both bacteria, especially against P.
aeruginosa [74].
Table 1 summarizes different studies where various antibiotics have
been incorporated in wound dressings to improve their bactericidal
activity.
Despite of several antibiotics be available to treat skin infections,
their recurrent use can trigger bacterial resistance [87]. In literature,
various studies report that an improper use of antibiotics leads to the
development of new resistance mechanisms by bacteria, thus causing
their global dissemination [88]. More than 70% of the bacteria that are
responsible for wound infections display resistance to at least one of the
antibiotics used in the clinic [89]. Methicillin-resistant Staphylococcus
aureus (MRSA) and vancomycin-resistant enterococci are two multi-
resistant bacteria that are involved in skin infections [88]. Such type of
infections are a major health issue, since vancomycin belongs to the
latest generation of antibiotics and it is assumed that it is the most
effective agent against S. aureus [89].
The number of multidrug resistant bacteria is increasing at an
alarming rate, i.e. bacteria are gaining resistance to all known classes of
natural and synthetic antibiotics leading to an urgent need for new
therapeutic alternatives [90]. Nanomedicine tools, particularly nano-
particles, constitute a different approach for the development of new
antimicrobial agents [91].
4.2. Nanoparticles as potential antimicrobial agents
Based on the data available in literature, nanoparticles (NPs) are
regarded as promising alternatives to conventional antibiotics, since
they display bactericidal activity against a large number of strains and
are able to minimize the undesirable side effects of drugs and do not
trigger microbial resistance [92,93]. Due to the intrinsic properties
displayed by NPs, they have been used in different therapeutic ap-
proaches that aim to circumvent the problems associated with the ac-
quisition of resistance to antibiotics by bacteria.
NPs alone can perform their bactericidal effect through direct con-
tact with the bacterial cell wall, through the release of toxic metal ions
or by the generation of Reactive Oxygen Species (ROS) [94]. When NPs
are in contact with bacterial cells walls, the positively-charged NPs are
attracted by the negatively-charged groups found in bacteria surfaces
(lipopolysaccharides in gram-negative and teichoic acid/peptidoglycan
in gram-positive). Then, van der Waals forces, receptor-ligand, and
Fig. 2. Representation of the different targets of antibiotic agents within bacteria.
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hydrophobic interactions are established and the cell wall permeability
is altered through the formation of “pores” at bacteria surface, leading
to its disruption and consequent loss of intracellular components [95].
At the same time, NPs can also cross the cell wall and affect metabolic
pathways, or even target mitochondria and cause its disruption and,
consequently, induce ROS production [96]. In addition, NPs can also
affect proton efflux pumps resulting in a serious pH deregulation and on
the variation of membrane’s surface charge [94]. Furthermore, NPs can
likewise interact with DNA, lysosomes, ribosomes, and enzymes,
leading to oxidative stress, electrolyte imbalance, enzyme inhibition,
protein deactivation and variations in the gene expression profile [97].
Fig. 3 presents the main bacterial targets of NPs and also some examples
of NPs that have been used in the treatment of skin infections.
Among the available NPs, silver nanoparticles (AgNPs) have gained
considerable attention owing to their broad inhibitory activity towards
nearly 650 species of microbes, and more importantly, against anti-
biotic resistant bacteria [98]. With the advancement of nano-
technology, the scientific community was able to enhance the anti-
microbial properties of silver, and consequently decrease silver NPs
minimum inhibitory concentration (MIC), as well as reduce the possible
interference of AgNPs in the wound healing process [99]. Such devel-
opments trigger the use of AgNPs in the production of wound dressings
and their subsequent introduction in the market [100]. Acticoat®,
Aquacel Ag® and Silvasorb® are examples of AgNPs containing dres-
sings [101].
In 2013, Jian Wu and collaborators developed a new method to
produce a BC hybrid gel-membranes containing AgNPs. The anti-
bacterial activity of AgNP-BC membranes was investigated against
gram-negative (E. coli and P. aeruginosa) and gram-positive (S. aureus)
bacteria. For comparative purposes, they also used a commercial silver-
Table 1
Wound dressings functionalized with antibacterial agents.
Antibiotic Wound dressing Materials Tested bacteria Ref.
Beta-lactams Ceftadizime Electrospun membrane SF/Gelatin P. aeruginosa [75]
Film Collagen/CMGG/EDA S. aureus
P. aeruginosa
[76]
Ampicillin Electrospun membrane PCL S. aureus
K. pneumoniae
[77]
Hydrogel PVA/SA E. coli [78]
Cefazolin Electrospun membrane Gelatin S. aureus [79]






Hydrogel PVA/Cellulose S. aureus
E. coli
[81]




Neomycin Electrospun membrane PSSA-MA/PVA S. aureus
E. coli
[82]

















Moxifloxacin Electrospun membrane PVA/SA P. aeruginosa
S. aureus
[85]
Sulphonamides Sulfadiazine Film BC/SA; CS/CHI E. coli
S. aureus
[53,74]




Electrospun membrane PCL/PVA S. aureus [52]
Sulfanilamide Fiber Alginate E. coli
S. aureus
[86]
Tetracyclines Doxycycline Film Collagen/DHBA/GMs P. aeruginosa [54]




Hydrogel OAlg/CMCS/GMs E. coli
S. aureus
[63]
Glycopeptides Vancomycin Hydrogel SF/GMs E. coli
S. aureus
[50]
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containing dressing (Coloplast®Ag non-adhesive foam dressing). The
obtained results revealed that the composite membranes loaded with
AgNPs inhibited the growth of all tested bacteria. No inhibitory effect
was observed for the pure BC membrane (control), thus demonstrating
the crucial role of AgNPs in conferring antimicrobial properties to the
produced dressings. In comparison to results obtained for a commercial
dressing, no significant difference was observed, meaning that the an-
timicrobial dressing produced in this study has potential to be used as
an effective wound dressing [102]. In another study, Augustine et al.
produced a polycaprolactone (PCL) electrospun membranes loaded
with AgNPs to be used as wound dressings. The fabricated membranes
showed excellent antibacterial activity against both S. aureus and E. coli
[103].
In recent studies, the antimicrobial properties of metallic nano-
composites were combined with natural products, in order to increased
their antibacterial effect and biocompatibility [104]. Anisha and their
co-workers developed an antimicrobial sponge composed by CS, Hya-
luronic acid (HA) and nano silver (nAg) to treat diabetic foot ulcers. The
produced sponges showed antimicrobial effect against E. coli, S. aureus,
P. aeruginosa and K. pneumonia. Further, those sponges loaded with
higher nAg (0.005%, 0.01% and 0.02%) concentrations were the most
effective in reducing the in vitro growth of MRSA [105].
Other studies where AgNPs and other metal nanoparticles have been
used to confer antimicrobial properties to the wound dressings are
summarized in Table 2.
Despite of the bactericidal activity presented by NPs, some studies
report that the same properties that make NPs so unique (small size,
large surface area, chemical composition, solubility and geometry)
could also be hazard to the human health, i.e. NPs due to their size can
easily enter the human body and cross various biological barriers,
reaching the most sensitive organs and disrupt the cell normal bio-
chemical pathways [96,117]. Costa et al., demonstrated that AgNPs
decrease the activity of mitochondrial respiratory chain complexes I, II,
III, and IV from Wistar rats tissues that were analyzed (brain, skeletal
muscle, heart and liver) [118]. Furthermore, Botelho et al. demon-
strated that TiO2 NPs induce tumor-like phenotypes in human gastric
epithelial cells [119].
Regardless of the several studies available in literature, the cyto-
toxic profile of a particular NP must be characterized in deeper detail
for a particular therapeutic purpose [120]. One strategy that is cur-
rently being followed to reduce the possible toxicity associated with
NPs use, is based on the obtainment of these carriers from natural
sources, namely plant extracts, to be incorporated in wound dressings.
4.3. Natural products
Nowadays, an increasing number of wound dressings have been
functionalized with compounds obtained from natural sources, to
Fig. 3. Representation of NPs targets in the bacteria and some examples of NPs that have been used as antimicrobial agents.
Table 2
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increase their antimicrobial activity [121,122]. Table 3 summarizes
some studies where natural products displaying bactericidal activity
were incorporated into wound dressings.
4.3.1. Honey
Honey has been regarded since the ancient times as a natural
healing agent. Due to its antimicrobial activity and capacity to perform
the topical nutrition to the wound, debriding activity, minimize in-
flammation and stimulate angiogenesis, granulation, wound contrac-
tion and epithelialization, honey has been incorporated into wound
dressings [131,132]. Different honey-impregnated dressings are already
available in the market, like MediHoney®, Activon Tulle®, Algivon® and
Actilite® [132].
Honey’s antimicrobial activity has been attributed to its acidity, low
water content, and presence of antimicrobial substances such as hy-
drogen peroxide, antimicrobial peptide bee defensin-1, flavonoids, and
phenolic acids [133–136]. The acidic character exhibited by honey
results from the presence of gluconic acid and some authors believe that
the acidic pH of honey may aid macrophages to kill bacteria and pre-
vent microbial biofilm formation [137,138]. In turn, the low water
content (< 20%) provides an unfavorable environment for micro-
organism survival and growth. High osmolarity inhibits microbial
growth, since water molecules are chemically tied to the sugar mole-
cules, leading to an inappropriate environment for organisms survival
[139,140]. Lastly, the production of hydrogen peroxide by honey is
responsible for the bacterial growth inhibition, i.e. hydrogen peroxide
is able to react with the cell wall, lipids, proteins and nucleic acids
available in bacteria [141,142]. In Fig. 4 are illustrated the bacterial
activities exhibited by honey.
Although, honey in the presence of catalase (an enzyme that de-
grades hydrogen peroxide) displays a decreased antimicrobial activity
[131]. To surpass this drawback, Manuka Honey (MH), which is ob-
tained from the manuka tree (Leptospermum scoparium), unlike other
honeys, contains a non-peroxide component, that is not degraded by
catalase, is able to sustain its antibacterial activity in biologic fluids
[131,132]. MH inhibits the growth of a broad range of microorganisms
(including gram-positive strains such as MRSA and S. pyogenes, as well
as gram-negative strains like E. coli, Proteus mirabilis (P. mirabilis), En-
terobacter cloacae, and P. aeruginosa) and avoids biofilm formation at
the wound site [143]. Furthermore, Packer et al. have described that
methylglyoxal (MGO), a component of MH, interferes with ribosome
and its translational capacity (see further details in Fig. 4) [131].
Bulman et al. incorporated MGO as a functional antibacterial agent
into polyvinyl alcohol fibers. The obtained results confirmed that the
fibers containing MGO exhibited bactericidal activity against E. coli and
S. aureus [144]. Moreover, Yang et al., incorporated MH in an elec-
trospun membrane produced with silk fibroin (SF), for being used as an
antimicrobial wound dressing. The SF/MH fibrous matrices presented
antibacterial activity against both gram-positive (MRSA and S. aureus)
and gram-negative (E. coli and P. aeruginosa) bacteria [145].
4.3.2. Essential oils
In addition to honey, essential oils (EOs) have been incorporated as
antibacterial agents in bioactive wound dressings. Essential oils, also
called volatile natural mixtures, are plant secondary metabolites that
exhibit antioxidant, antiviral, anticancer, insecticidal, anti-in-
flammatory, anti-allergic and antimicrobial properties [146].
Different authors stated that the antimicrobial activity of EOs that
are usually incorporated in wound dressings is attributed to phenolic
compounds, specifically to thymol and carvacrol [131,132,143]. Ka-
voosi et al., reported that EOs attack the phospholipids present in the
cell membranes and the lipids available on the cell wall of the bacteria,
leading to an increased permeability and ultimately to cell lysis. Such
results in the cytoplasm leakage, pH decrease, and loss of cellular
processes, like ATP biosynthesis, DNA transcription and protein
synthesis. Moreover, Altiok et al. described that EOs disturbs the
function of the cytoplasmic membrane, by disrupting the active trans-
port of nutrients through the cell membrane, and coagulation of bac-
teria cell contents [147]. In Fig. 5 are illustrated different mechanisms
through which EOs exert their antimicrobial activity.
Amongst the different EOs components, cinnamaldehyde, geraniol,
thymol analogues, menthol and carvacrol (a major ingredient of Zataria
multiflora EO) are the most used for antibacterial purposes. Liakos
et al., incorporated 1% and 5% of EOs (cinnamon, lemongrass and
peppermint) in cellulose-based fibrous dressings and they noticed that
the fibrous dressings were able to inhibit the growth of E. coli, even
when small amounts of EOs were used [148]. In another study, Liakos
et al. prepared polymeric composite films with sodium alginate (NaAlg)
incorporating different EOs (chamomile blue, cinnamon, lavender, tea
tree, peppermint, eucalyptus, lemongrass and lemon oils) and three
different concentrations of EOs were tested (16%, 50% and 66%). They
produced dressings able to inhibit E. coli growth [149].
4.3.3. Chitosan
Chitosan (CS) and its derivatives display a high antimicrobial ac-
tivity against fungi, bacteria, algae and viruses [150]. In the literature
there are at least three mechanisms proposed for explaining the anti-
bacterial activity of CS (as depicted in Fig. 6) [151]. The most accepted
mechanism proposes that CS antimicrobial activity results from the
electrostatic interactions occurring between the positively-charged
groups of chitosan (amine groups of glucosamines) and the negatively-
charged groups available on the bacterial cell wall (surface components
like peptidoglycans) [152]. This electrostatic interaction can affect the
permeability of the cell wall, thus causing internal osmotic imbalances
and consequently inhibit the growth of microorganisms. On the other
hand, the electrostatic interactions can induce the hydrolysis of the
peptidoglycans of the microorganisms’ cell wall, prompting the leakage
of intracellular electrolytes [151]. The second proposed mechanism
involves the formation of a polymeric envelope around bacteria,
leading to the inhibition of cell exchanges and nutrients absorption
[152]. The last mechanism includes the chelation of trace metals and
oligo-elements that are essential for bacterial growth, i.e. the amino
groups of CS might interact with essential trace metals and thereby
inhibit the production of toxins and microbial growth [151,152]. These
specific properties triggered its use in the production of wound dres-
sings available in the market, such as HidroKi®, Patch®, Chitopack®,
Table 3
Wound dressings containing natural antibacterial agents isolated from plants.
Natural products Wound
dressing
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Fig. 4. Representation of the mechanisms proposed to explain the bactericidal activity exhibited by Honey and MH.
Fig. 5. Representation of phenol (active component of essential oils) targets in bacteria.
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Tegasorb® and KytoCel® [153].
Antunes et al. produced an electrospun membrane comprised by
deacetylated/arginine modified chitosan (CS-A) to be used as a wound
dressing. In this study, CS was modified with arginine to increase the
number of positively charged groups available on material’s surface, to
enhance its electrostatic interaction with bacteria cell wall. The
obtained results highlight the importance of coupling arginine residues
to CS, since the modified CS exhibit a much higher antimicrobial ac-
tivity [154]. Furthermore, Yuan et al. prepared a CS and polyethylene
oxide (PEO) nanofibrous meshes for wound healing application. The
electrospun mesh was able to significantly reduce the bacterial colonies
attached to the membrane surface. In addition, those materials with a
higher concentration of chitosan present a greater bactericidal effect
[155]. Other studies where CS has also been used for the production of
antimicrobial wound dressings are summarized in Table 4.
5. Concluding remarks and future prospects
Nowadays, nearly everyone has already suffered an open skin
wound as a consequence of a cut, burn, diseases (e.g. diabetes) or
surgical interventions. In some circumstances those wounds can easily
be contaminated by different pathogens found in the surrounding en-
vironment, endogenous microbes living in the mucous membranes, or
by the microflora available on the adjacent skin. Gram-positive bac-
teria, like E. coli and P. aeruginosa, and gram-negative bacteria, such as
S. aureus, are the predominant pathogens responsible for skin con-
tamination and subsequent infections. Wound dressings displaying an-
timicrobial activity started to be produced in order to surpass this
health problem. Different strategies, comprising materials’ surface
functionalization with different groups or antimicrobial agents in-
corporation (antibiotics, nanoparticles and natural products), have
been used to confer bactericidal activity to dressings. However, despite
of developments attained so far, further improvements of these type of
dressings is demanded. In a near future it is expected that the co-ad-
ministration of antibacterial agents leads to an increased therapeutic
outcome. Furthermore, the development of new NPs or the loading of
antimicrobial agents into nanodevices may open new avenues to treat
Fig. 6. Representation of the mechanisms proposed to explain the antibacterial activity of Chitosan.
Table 4
Chitosan-based wound dressings for skin regeneration applications.
Chitosan-based wound
dressing
Materials Tested bacteria Ref.


















CS/Aloe vera E. coli
S. aureus
[153]
Hydrogel CS/Agarose E. coli
S. aureus
[162]
Sponge CS/PCD S. aureus [163]
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infected wounds. In addition, dressings containing sensors and ther-
apeutic molecules may also be produced in order to simultaneously
perform the monitoring and treatment of an infected wound.
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